Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/39981
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVanhoutte, Thomas-
dc.contributor.authorSPRANGERS, Ben-
dc.date.accessioned2023-04-25T13:51:15Z-
dc.date.available2023-04-25T13:51:15Z-
dc.date.issued2023-
dc.date.submitted2023-04-12T12:34:26Z-
dc.identifier.citationClinical Kidney Journal, 16 (4) , p. 603 -610-
dc.identifier.urihttp://hdl.handle.net/1942/39981-
dc.description.abstractBesides true acute kidney injury (AKI), the occurrence of pseudo-AKI has been associated with several targeted agents. To improve the management of cancer patients treated with targeted agents, we need to be aware of this and use diagnostic approaches to differentiate between pseudo-AKI and AKI. In an article by Wijtvliet et al. in this issue of CKJ, tepotinib is added to the list of targeted agents associated with pseudo-AKI. In this editorial we discuss the current literature regarding pseudo-AKI and true AKI associated with targeted agents, and subsequently propose a management strategy to monitor kidney function in patients treated with targeted agents.-
dc.language.isoen-
dc.publisherOXFORD UNIV PRESS-
dc.rights© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com-
dc.subject.otheracute kidney injury-
dc.subject.otheracute kidney injury-
dc.subject.othercreatinine-
dc.subject.othercreatinine-
dc.subject.othercystatin C-
dc.subject.othercystatin C-
dc.subject.otherkidney function-
dc.subject.otherkidney function-
dc.subject.othertargeted therapies-
dc.subject.othertargeted therapies-
dc.titlePseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker-
dc.typeJournal Contribution-
dc.identifier.epage610-
dc.identifier.issue4-
dc.identifier.spage603-
dc.identifier.volume16-
local.format.pages8-
local.bibliographicCitation.jcatA2-
dc.description.notesSprangers, B (corresponding author), Ziekenhuis Oost Limburg, Genk, Belgium.; Sprangers, B (corresponding author), UHasselt, Biomed Res Inst, Dept Immunol & Infect, Diepenbeek, Belgium.-
dc.description.notesben.sprangers@zol.be-
local.publisher.placeGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedEditorial Material-
dc.identifier.doi10.1093/ckj/sfad011-
dc.identifier.pmid37007700-
dc.identifier.isi000950493000001-
local.provider.typewosris-
local.description.affiliation[Vanhoutte, Thomas] Univ Hosp Leuven, Dept Nephrol, Leuven, Belgium.-
local.description.affiliation[Sprangers, Ben] Ziekenhuis Oost Limburg, Genk, Belgium.-
local.description.affiliation[Sprangers, Ben] UHasselt, Biomed Res Inst, Dept Immunol & Infect, Diepenbeek, Belgium.-
local.uhasselt.internationalno-
item.fulltextWith Fulltext-
item.fullcitationVanhoutte, Thomas & SPRANGERS, Ben (2023) Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker. In: Clinical Kidney Journal, 16 (4) , p. 603 -610.-
item.accessRightsOpen Access-
item.contributorVanhoutte, Thomas-
item.contributorSPRANGERS, Ben-
crisitem.journal.issn2048-8505-
crisitem.journal.eissn2048-8513-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Pseudo-AKI associated with targeted anti-cancer agents—the truth is in the eye of the filtration marker.pdfPublished version355.43 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

5
checked on Jul 10, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.